MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Adenocarcinoma
/ drug therapy
Antibodies, Monoclonal
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
Esophageal Neoplasms
/ drug therapy
Esophagogastric Junction
/ pathology
Female
Humans
Male
Neoplasm Staging
Receptor, ErbB-2
/ metabolism
Stomach Neoplasms
/ drug therapy
Treatment Outcome
HER2
I-O combination
LAG-3
PD-1
checkpoint inhibitor
first-line therapy
gastric cancer
gastroesophageal adenocarcinoma
gastroesophageal junction cancer
immuno-oncology
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
3
12
2020
medline:
16
10
2021
entrez:
2
12
2020
Statut:
ppublish
Résumé
Standard-of-care, first-line therapy for patients with advanced HER2+ gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Margetuximab is an Fc-optimized mAb that binds HER2. Retifanlimab, a humanized IgG4 mAb, binds to PD-1 and blocks its interaction with PD-L1/2. Tebotelimab, an IgG4κ bispecific DART
Identifiants
pubmed: 33263418
doi: 10.2217/fon-2020-1007
doi:
Substances chimiques
Antibodies, Monoclonal
0
Biomarkers, Tumor
0
Receptor, ErbB-2
EC 2.7.10.1
margetuximab
K911R84KEW
Banques de données
ClinicalTrials.gov
['NCT04082364']
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1155-1164Subventions
Organisme : MacroGenics, Inc.